Precigen, Inc. ( (PGEN) ) has released its Q3 earnings. Here is a breakdown of the information Precigen, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Precigen, Inc. is a biopharmaceutical company focused on developing innovative precision medicines to treat challenging diseases, particularly in the fields of immuno-oncology, autoimmune disorders, and infectious diseases.
In its latest earnings report, Precigen announced significant milestones, including the FDA approval and commercial launch of PAPZIMEOS, the first and only treatment for adults with recurrent respiratory papillomatosis (RRP). The company also highlighted its financial performance for the third quarter of 2025.
Key highlights from the report include the successful launch of PAPZIMEOS in the US, with over 100 patients registered and substantial progress in securing private health insurance coverage. Additionally, the company reported long-term durability data showing significant reductions in surgeries for RRP patients treated with PAPZIMEOS. Financially, Precigen’s cash and investments totaled $123.6 million, and the company secured a $125 million credit facility to support its operations.
Despite these achievements, Precigen reported a net loss attributable to common shareholders of $325.3 million for the third quarter, largely due to non-cash items such as the increase in warrant liabilities and a deemed dividend on preferred stock. However, the company remains optimistic about its financial position, expecting its current cash reserves to support operations until reaching cash flow break-even.
Looking ahead, Precigen is focused on expanding the availability of PAPZIMEOS in Europe and continuing its research on other promising therapies. The company is committed to advancing its strategic objectives and driving sustainable growth in the biopharmaceutical sector.